Loading clinical trials...

Acute Intermittent Hypoxia in Persons With Multiple Sclerosis | Clinical Trials | Clareo Health

COMPLETEDNA

Acute Intermittent Hypoxia in Persons With Multiple Sclerosis

Evaluating the Use of Acute Intermittent Hypoxia to Improve Symptoms in Persons With Multiple Sclerosis

NCT04280484•Shirley Ryan AbilityLab

Summary

The overall objective of this project is to investigate the effectiveness of Acute Intermittent Hypoxia (AIH), to improve muscle strength and activity level in individuals with relapsing-remitting MS.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have relapsing-remitting MS
•Volitional ankle plantar flexion strength in at least one leg
•Are relapse free for 30 days
•Patient-Determined Disease Steps scale score between 3 and 5 (3=gait disability to 5=late cane, need cane to walk 25 feet)

Exclusion Criteria

•Currently taking antispasticity medications,
•Have cardiovascular or respiratory/pulmonary disorders, metabolic dysfunction, or prior diagnoses of obstructive sleep apnea
•Pregnant or nursing women (safety for developing fetus or infant is unknown)
•Cognitive concerns (must be able to consent to study, follow steps)

Locations (1)

Shirley Ryan AbilityLab

Chicago, Illinois, United States

Key Dates

Start Date

June 18, 2018

Primary Completion Date

October 10, 2019

Completion Date

December 30, 2019

Last Updated

February 24, 2020

Enrollment

ACTUAL participants

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

Intermittent Hypoxia

OTHER

Sham Hypoxia

OTHER

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT05359653

Multiple Sclerosis (MS)Multiple Sclerosis, Relapsing-Remitting+5 more

View study

RECRUITINGNA

Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

NCT06390930

Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 24, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Acute Intermittent Hypoxia in Persons With Multiple Sclerosis

Inclusion Criteria

Exclusion Criteria

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis

Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS

The Synergistic Effects of AIH and FES in Persons With MS